Galectin Therapeutics | GALT - Interest Expense On Debt

Stock Price
2.97
Daily Change
-0.01 -0.17%
Monthly
-4.97%
Yearly
103.08%
Q1 Forecast
2.88

Galectin Therapeutics reported $1.27M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Galectin Therapeutics USD 1.27M 220K Jun/2024
Gilead Sciences USD 255M 1000K Dec/2025
Immunic 400K 400K Dec/2024
Incyte USD 582K 10K Dec/2025
Merck USD 412M 85M Dec/2025